TELA Bio Appoints William Plovanic to Board

TELA Bio ( (TELA) ) has issued an announcement.

On October 31, 2025, TELA Bio, Inc. expanded its Board of Directors from six to seven members by appointing William Plovanic as a Class I director, with his term set to expire at the 2026 Annual Meeting of Stockholders. Mr. Plovanic, with extensive experience in healthcare equity research and leadership roles in medical technology companies, is expected to bring valuable insights to TELA Bio. His appointment, accompanied by an initial equity award, aligns with the company’s non-employee director compensation policy, potentially enhancing TELA Bio’s strategic direction and governance.

The most recent analyst rating on (TELA) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.

Spark’s Take on TELA Stock

According to Spark, TipRanks’ AI Analyst, TELA is a Underperform.

TELA Bio’s overall stock score is primarily impacted by its financial performance and technical analysis. Despite revenue growth, the company faces significant profitability challenges, reflected in its negative P/E ratio and cash flow issues. The technical indicators suggest a bearish trend, further weighing down the score. The earnings call highlighted positive revenue growth, but this was not enough to offset the financial and technical challenges.

To see Spark’s full report on TELA stock, click here.

More about TELA Bio

TELA Bio, Inc. operates in the medical technology industry, focusing on developing and commercializing soft tissue reconstruction solutions. The company primarily targets the healthcare sector with its innovative products designed to improve patient outcomes.

Average Trading Volume: 98,533

Technical Sentiment Signal: Strong Sell

Current Market Cap: $48.73M

Find detailed analytics on TELA stock on TipRanks’ Stock Analysis page.